ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I ...

He was the beloved husband of 66 years to Anna (Ann) M. (Gurley) Foust. Born June 12, 1931 in Spry, he was a son of the late Paul E. and Ada V. (Slenker) Foust. Gene loved God and cherished ...

Get the inside scoop on how colleges assess your high school and its course rigor. Featuring a former Admissions Officer, you'll gain crucial insights and actionable strategies during this 60-min ...

Jeff Spry is a screenwriter and freelance journalist covering TV, movies, video games, books, and comics. His work has appeared at Space.com, SYFY Wire, Inverse, Collider, Bleeding Cool and elsewhere.

ARS Pharmaceuticals Inc (NASDAQ:SPRY) successfully launched neffy, the first needle-free epinephrine treatment, with $7.8 million in US net product revenue in Q1 2025. The company expanded ...

Spry Digital's chief relationship officer shares the multi-pronged approach that revitalized company culture after a tumultuous year. HR Awards 2025: HR manager transforms firm's culture HR Awards ...

Paramount+'s flagship 'Star Trek' TV series launches back into our living rooms this summer. July 2025 is heating up to be one of the most geekiest release months in recent memory, first on the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Good morning and welcome to ARS Pharmaceuticals' Conference Call. At this time, all participants are in listen-only mode. After the company's prepared remarks, we will open the lines for questions ...

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago. These figures are ...